Please login to the form below

Acadia

This page shows the latest Acadia news and features for those working in and with pharma, biotech and healthcare.

Acadia’s drive to extend use of Nuplazid hits a wall

The drug has failed the late-stage ENHANCE trial in schizophrenia inadequately controlled by currently-approved drugs, viewed as one of Acadia’s biggest opportunities to extend the franchise. ... Shares in Acadia were down 16% remarket in the wake of

Latest news

New leader at Medivir after setbacks

s board in May having previously had a 15-year stint as CEO of Acadia Pharma which came to end in 2015 after the company was forced to delay a filing
Nuplazid backed by FDA panel as first-ever Parkinson's psychosis drug

Concludes Acadia Pharmaceuticals’ drug provides ‘modest but meaningful’ benefits. Acadia Pharmaceuticals is celebrating an FDA panel verdict that could set its Nuplazid drug up to be the first approved therapy for ... However, there were some
Clouded vision

AGN 203818 is an orally active, α-adrenoreceptor agonist that was discovered as part of a research programme between Allergan and ACADIA.
Striking a balance

Xsira Pharmaceuticals, 7TM Pharma, Acadia Pharmaceuticals, Glenmark Pharmaceuticals, Esteve, Vernalis, OSI Pharmaceuticals, EPIX Pharmaceuticals, Bayer and Novasite Pharmaceuticals are all undertaking separate research projects to develop CB1
Thomson Scientific publishes quarterly review of phase changes in industry pipeline

Compound. Indication. Company. trazodone. Depression. Labopharm. pimavanserin. Schizophrenia. Acadia Pharmaceuticals. salmon calcitonin.

More from news
Approximately 2 fully matching, plus 4 partially matching documents found.

Latest Intelligence

Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

Jacob Plieth at Vantage recently highlighted this trend, with companies like Tesaro, Clovis Oncology and Acadia failing to meet revenue expectations for their new launches.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

Damien McDevitt moves from GSK to Acadia Pharmaceuticals

US biopharmaceutical company Acadia Pharmaceuticals has appointed Damien McDevitt (pictured) as senior vice president of corporate development. ... Meanwhile, Acadia’s SVP, technology development and operations Jim Nash will retire in January.
Juniper Pharmaceuticals adds to board of directors

Dr Gray has over 20 years of biotechnology and biopharmaceutical experience and is the owner and president of Gray Strategic Advisors as well as serving on the boards of Acadia Pharmaceuticals,
Srdjan Stankovic joins Acadia Pharmaceuticals

He moves to the San Diego biopharma from Alkermes. San Diego biopharmaceutical company Acadia Pharmaceuticals has appointed Srdjan (Serge) Stankovic as executive vice president, head of research and development. ... Steve Davis, Acadia's president

More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Account Director – UK Office: Excellent salary and benefits

Client Services Director- Flexible Working: Negotiable

Account Manager – Healthcare advertising: Salary TBC

Strategic Planner, Healthcare Advertising Agency: Salary TBC

Senior Medical Writer: Competitive salary plus benefits

Events Executive: DOE

Subscribe to our email news alerts

PMHub

Add my company

Red Health

Red Health was formed in 2007 to bring something fresh to the healthcare PR world. Our approach was simple –...

Latest intelligence

Report: Customer experience, shaping digital healthcare: In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Encouraging signs in biomarker R&D: The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it: What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...